NCT04790682 LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
| NCT ID | NCT04790682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Metastatic Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-05-22 |
| Primary Completion | 2029-06-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2021-05-22 with a primary completion date of 2029-06-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.
Eligibility Criteria
Inclusion Criteria: 1. Histologically-proven NSCLC. 2. Age ≥ 18 years. 3. Advanced or metastatic stage IV. 4. Treatment-naïve patient. 5. Eligibility to first-line treatment with immune checkpoint inhibitor. 6. Measurable disease according to RECIST 1.1 criteria on CT-Scan. 7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy. 8. No ALK or EGFR gene alteration. 9. Availability of tumor tissue for NGS analysis (7 slides). 10. PS 0 or 1. 11. Signed informed consent of the patient. Exclusion Criteria: 1. No social security affiliation. 2. Person under legal protection. 3. Pregnant and breastfeeding women. Patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information
Contact & Investigator
Nicolas GIRARD, PR
STUDY DIRECTOR
INSTITUT CURIE - Medical Oncology
Frequently Asked Questions
Who can join the NCT04790682 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04790682 currently recruiting?
Yes, NCT04790682 is actively recruiting participants. Contact the research team at marieemmanuelle.legrier@curie.fr for enrollment information.
Where is the NCT04790682 trial being conducted?
This trial is being conducted at Boulogne-Billancourt, France, Paris, France, Saint-Cloud, France.
Who is sponsoring the NCT04790682 clinical trial?
NCT04790682 is sponsored by Institut Curie. The principal investigator is Nicolas GIRARD, PR at INSTITUT CURIE - Medical Oncology. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.